Nxera Pharma (4565) Fundamentals 2026 — Revenue Analysis | SniperIQ
Nxera Pharma (4565) is a JP-listed Healthcare company in Biotechnology with a market capitalization of ¥84.5B, trading at ¥921.00 on the JPX. This SniperIQ fundamentals page covers Nxera Pharma's valuation, profitability (net margin -29.1%), revenue (¥29.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Nxera Pharma's market cap?
Nxera Pharma (4565) has a market capitalization of approximately ¥84.5B, trading at ¥921.00 on the JPX. Market cap moves with the live share price.
What is Nxera Pharma's P/E ratio?
Nxera Pharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Nxera Pharma?
Nxera Pharma runs a net profit margin of -29.1%, a gross margin of 77.5%, and an operating margin of -6.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Nxera Pharma generate?
Nxera Pharma reported revenue of ¥29.6B for fiscal year 2025, with net income of -¥12.5B and earnings per share (EPS) of -138.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Nxera Pharma pay a dividend?
Nxera Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Nxera Pharma financially healthy?
Nxera Pharma carries a debt-to-equity ratio of 0.88x and a current ratio of 2.61x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Nxera Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nxera Pharma (4565) the key facts are: market cap ¥84.5B, revenue ¥29.6B, 52-week range 723-1247. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Nxera Pharma's full fundamentals live
Get Nxera Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.